Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand (Diabetes Therapy, (2023), 14, 3, (531-552), 10.1007/s13300-023-01371-y)
Deerochanawong C., Krittayaphong R., Romano J.G.U., Rhee N.A., Permsuwan U. Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand (Diabetes Therapy, (2023), 14, 3, (531-552), 10.1007/s13300-023-01371-y). Diabetes Therapy (2023). doi:10.1007/s13300-023-01392-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82530
Title
Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand (Diabetes Therapy, (2023), 14, 3, (531-552), 10.1007/s13300-023-01371-y)
There are few errors in the original publication; the fourth author name is published as Nicolai R. Rhee, Novo Nordisk, Bangkok, Denmark. The correct name and affiliation is ‘‘Nicolai A. Rhee, Novo Nordisk, Bangkok, Thailand’’. There is an update in legend for Fig. 2. The correct legend given below.
